SV

Street Verdict

Analyst Scorecard

A record of what Nikhil Ranka said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on Biocon, expecting another 10-15% upside from current levels, with a fair value close to ₹500. This outlook is driven by a strong biosimilar business, a ₹300 crore sequential revenue jump, stronger margins, upcoming biosimilar launches, consistent profitability guidance, and eased USFDA norms on interchangeability.”
BioconBullishCalled 14 Nov 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Nikhil Ranka’s full track record